A pharmaceutical cannabinoid developer that built its entire business around federal compliance is now suing to undo the Trump administration's cannabis rescheduling order - arguing that the new framework rewards state-market operators who spent years in a federal gray zone while penalizing companies that chose the harder, more expensive path. MMJ International Holdings filed a petition for review on May 28 in the U.S. Court of Appeals for the D.C. Circuit, joining a consolidated challenge that now includes five separate petitions targeting Acting Attorney General Todd Blanche's April 22 order reclassifying certain cannabis products from Schedule I to Schedule III under the Controlled Substances Act.
What the Order Actually Does - and Why MMJ Finds It Objectionable
The rescheduling order, which took effect immediately upon publication in the Federal Register on April 28, covers two categories of cannabis products: FDA-approved drug products containing marijuana, and products operating under qualifying state-issued medical marijuana licenses. Alongside the reclassification, the order eliminates the Section 280E tax deduction disallowance for state-licensed cannabis businesses - one of the most operationally consequential provisions for dispensary operators and multi-state companies that have carried heavy effective tax burdens for years because they could not deduct ordinary business expenses the way any other retail or manufacturing business can.
For most of the licensed cannabis industry, those two changes represent meaningful wins. The 280E relief alone has been a defining financial constraint; operators unable to deduct payroll, rent, utilities, or marketing costs have watched effective tax rates compress margins that were already under pressure from state excise taxes, local fees, and compliance overhead. The new DEA registration pathway for state licensees gives operators a route to federal legitimacy they have never had.
Here's the catch, from MMJ's perspective. The company spent years - and, according to its filings, millions of dollars - building a federally compliant pharmaceutical operation: DEA Schedule I analytical laboratory registration, FDA Investigational New Drug applications, and Orphan Drug Designation for Huntington's disease. MMJ BioPharma Labs and MMJ BioPharma Cultivation developed pharmaceutical soft-gel cannabinoid formulations under full FDA manufacturing controls. That is a structurally different - and structurally costlier - path than operating under a state cannabis license. And now, the order's expedited DEA registration pathway gives state-licensed operators a fast lane to federal standing without subjecting them to the same criminal-history reviews, diversion-prevention controls, or public-interest scrutiny that pharmaceutical applicants like MMJ faced.
The petition frames this plainly as a "regulatory double standard" - a competitive injury cognizable under Article III. Whether federal courts agree is a separate question, but the underlying grievance has real-world business logic behind it.
The Constitutional Argument No One Saw Coming
MMJ brings something unusual to this litigation beyond the competitive-injury claim. The company's subsidiary, MMJ BioPharma Cultivation Inc., had previously sued over the constitutionality of the DEA's administrative law judge structure in a case against the Department of Justice. In that litigation - MMJ BioPharma Cultivation Inc. v. Bondi, filed in the District of Rhode Island - the DOJ formally conceded that the multiple layers of removal restrictions for administrative law judges under 5 U.S.C. § 7521 are unconstitutional under Article II and separation-of-powers doctrine.
That concession matters here because a DEA administrative hearing on the rescheduling order is currently scheduled to begin June 29, 2026 - before the same administrative structure the DOJ has already acknowledged is constitutionally defective. MMJ argues the rescheduling order compounds its injury by restructuring the scheduling framework while that structural flaw remains unresolved. It is a narrow but pointed argument, and it gives the coalition something procedurally concrete to anchor emergency stay requests around.
The full petition outlines 13 legal issues the petitioners intend to brief, including challenges under the major questions doctrine, the Administrative Procedure Act, the Fifth Amendment's equal protection clause, and the Supreme Court's Loper Bright decision, which curtailed judicial deference to agency interpretations of ambiguous statutes. That last one is worth watching. Loper Bright has become a live tool in regulatory challenges across industries, and its application to DEA scheduling authority - particularly where the administration used the treaty-implementation provision of the CSA to bypass standard notice-and-comment rulemaking - is genuinely unsettled legal territory.
Who Else Is in the Coalition - and What That Signals
MMJ is joined by four other petitioners: New Directions Addiction Recovery Services, an Illinois substance abuse recovery clinic; Dr. Kenneth Finn, a pain medicine specialist who held standing in the now-terminated DEA administrative hearing; Dr. Elizabeth "Libby" Stuyt, a Colorado addiction psychiatrist; and Cannabis Industry Victims Educating Litigators, known as CIVEL, an advocacy group representing individuals who claim harm from the cannabis industry.
The coalition is notably heterogeneous. Addiction medicine clinicians, a recovery services organization, and a pharmaceutical developer do not share identical interests - but they share a common objection to a rescheduling process they argue was rushed, procedurally irregular, and substantively unfair to stakeholders who had been participating in a formal administrative process that was then displaced. The D.C. Circuit has consolidated this petition with two earlier challenges: one filed May 4 by Smart Approaches to Marijuana and the National Drug and Alcohol Screening Association, and one filed May 22 by the attorneys general of Nebraska and Indiana (Louisiana subsequently withdrew).
What's striking here is the breadth of the opposition. This is not a simple industry versus government dispute. The petitioners span public health advocacy, pharmaceutical development, addiction medicine, and state government - which complicates any narrative that frames the rescheduling challenge as fringe opposition to an obviously popular policy.
What This Means for Operators, Investors, and Compliance Teams
To put it plainly: the rescheduling order's benefits are not banked yet. A court stay pending review would freeze both the 280E relief and the new DEA registration pathway for state operators, returning the industry to its prior federal posture. Vacatur of the order entirely would push cannabis back to Schedule I - unwinding every downstream gain the order produced. Neither outcome is the base case today, but both are legally possible outcomes of a consolidated challenge now pending before a federal appellate court.
For dispensary operators who have already restructured payroll, tax planning, or banking relationships around anticipated 280E relief, that uncertainty deserves a closer look at the litigation calendar. Near-term procedural milestones include oral argument scheduling, potential emergency stay motions, and any expedited consideration the court grants given the June 29 administrative hearing date. None of those timelines are resolved.
For pharmaceutical-track cannabis companies - those that have pursued DEA registration, FDA submissions, and IND applications rather than state license structures - the MMJ challenge represents something broader than one company's grievance. If the courts find that the expedited registration pathway for state operators constitutes cognizable competitive injury to federal-compliance-track developers, it could force a recalibration of how future scheduling or regulatory changes treat participants who built their businesses inside the federal framework from the start. That is a long shot, but it is not an implausible one.
The cannabis business has operated for years inside a compliance structure defined by exactly this kind of layered contradiction: federal prohibition alongside state-licensed markets, 280E applied to businesses state governments explicitly authorized, DEA registration requirements that governed some market participants but not others. The rescheduling order was supposed to begin resolving those contradictions. What the MMJ petition suggests is that resolving one layer of regulatory inconsistency can expose another - and that the companies most invested in federal legitimacy may have the most to say about how that resolution gets structured.
